Sign In
Buy DXCM
$72.77
-0.680 (-0.93%)
At Close: Jun 03, 2026
Portnoy Law Firm Announces Class Action on Behalf of DexCom, Inc. Investors
03:23pm, Tuesday, 28'th Oct 2025
LOS ANGELES, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DexCom, Inc., (“DexCom” or the "Company") (NASDAQ: DXCM) investors off a class action on behalf of investors that bought
DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor
02:04pm, Tuesday, 28'th Oct 2025
DexCom Inc (NASDAQ:DXCM) is facing renewed scrutiny after three people with diabetes reportedly died following issues with its G7 continuous glucose monitor, according to adverse event filings submitt
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed DexCom, Inc. (DXCM)
01:50pm, Tuesday, 28'th Oct 2025
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of N
Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption?
11:41am, Tuesday, 28'th Oct 2025
DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes markets.
ATLANTA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM). The lawsuit alleges that Defendant
Dexcom Appoints Euan Ashley to Board of Directors
04:15pm, Monday, 27'th Oct 2025
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--Dexcom Appoints Euan Ashley to Board of Directors.
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights
03:06pm, Monday, 27'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
12:15pm, Thursday, 23'rd Oct 2025
NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
10:00am, Saturday, 18'th Oct 2025
NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to conta
2 Stocks Down 17% and 21% to Buy Right Now
10:00am, Tuesday, 14'th Oct 2025
One way to earn above-average market returns -- which isn't always easy -- is to invest in companies that have lagged the market but are likely to recover over the long run. As the basic investing max
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
01:50pm, Monday, 13'th Oct 2025
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
05:44pm, Wednesday, 08'th Oct 2025
NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact D
DexCom May Be The Most Underrated Growth Story In Healthcare
06:39am, Monday, 06'th Oct 2025
DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% g
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM
12:45pm, Friday, 03'rd Oct 2025
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact
Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.
08:30am, Thursday, 02'nd Oct 2025
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2025 financial results after market close on Thursday, October 30, 2025. Management wi
